The FDA has approved trastuzumab deruxtecan for HER2-low breast cancer. BCSM FDAapproves
AstraZeneca's IV infusion is the first therapy approved for HER2-low breast cancer, a newly defined subset of HER2-negative breast cancer in which there are some HER2 proteins on the cell surface, but not enough to warrant classification as HER2-positive cancer, the agency said in aThe indication is for patients who have received prior chemotherapy in the metastatic setting or for patients whose cancer has returned during adjuvant chemotherapy or within 6 months of completing it.
Of these patients, 373 were randomly assigned to received trastuzumab deruxtecan every 3 weeks, and 184 were randomly assigned to receive physician's choice of chemotherapy (eribulin,
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
FDA considering 'dose-sparing' approach to increase availability of Jynneos vaccineHealth care providers could use one vial of the vaccine to administer up to five doses without an impact on safety or efficacy.
Baca lebih lajut »
Precision cancer targeting with antibody pairs - Nature BiotechnologyLogic-gated monoclonal antibodies have been designed to improve safety and efficacy NBTNV
Baca lebih lajut »
The Rehearsal strays further into Brechtian territoryOkay, class, today we're going to learn about “The Fielder Method”
Baca lebih lajut »
Can Mack Hollins Emerge As Raiders' WR3?One of the names to look out for Thursday night will be Las Vegas Raiders wide receiver Mack Hollins, a free agent signee this offseason.
Baca lebih lajut »
This Is the No. 1 Lung Cancer Symptom People Ignore — Best LifeOne particular lung cancer symptom often goes ignored, doctors say. Here's what you need to know, and when to see your healthcare provider.
Baca lebih lajut »
UK should move to one dose of HPV jab for teensTwo doses are now given but experts say one shot is enough to give protection against cervical cancer.
Baca lebih lajut »